40 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2026 PROCOS With roots dating back to 1945, PROCOS SpA has built a long-standing reputation as a key contributor to the pharmaceutical industry, specialising in the development and manufacture of small-molecule active pharmaceutical ingredients. As the company moves beyond eight decades of activity, it continues to evolve as a Contract Development and Manufacturing Organisation (CDMO), combining solid industrial experience with a forward-looking approach focused on innovation, quality and long-term partnerships. Over the years, PROCOS has consistently invested in new technologies and production capabilities to remain aligned with the changing needs of the global pharmaceutical market. This strategy has enabled the company to broaden its technological scope, including the expansion into Highly Potent APIs, while preserving its strong positioning in nonHP small-molecule synthesis, a core competence that has shaped its growth since the early 2000s. The recent completion of the first phase of R11 manufacturing facility represents a significant step within this long-term investment strategy. Starting in 2024 in approximately two years, all construction and installation activities, along with qualification phases and regulatory inspections, have been successfully completed. Following approval by the relevant authorities, the facility is now fully licensed and ready for cGMP production. R11 has been conceived as a flexible, multi-purpose GMP facility capable of supporting the manufacture of complex small molecules and advanced intermediates. The building extends across four levels and approximately 4,000 square metres, housing up to four independent production lines. These lines are equipped with large-scale reactors ranging from 1,000 to 6,000 litres, with centrifugation and highperformance drying systems designed to handle a broad spectrum of processes. This configuration allows PROCOS to efficiently manage projects spanning from preclinical development to commercial supply, ensuring smooth scalability and reliable continuity throughout the product lifecycle. It provides an additional 75 cubic metres of cGMP reactor capacity at the current site set-up.
RkJQdWJsaXNoZXIy MjY2OTA4MA==